Associated Papers
Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers.
Bignucolo A et al.
Expert Review of Clinical Pharmacology, 2022
Pharmacogenetics of healthy volunteers in Puerto Rico.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
Germline oncopharmacogenetics, a promising field in cancer therapy.
Pesenti C et al.
Cellular Oncology (dordrecht, Netherlands), 2015
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2010
Pharmacogenetics in chemotherapy of colorectal cancer.
Henriette Tanja L et al.
Best Practice & Research. Clinical Gastroenterology, 2009
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Toffoli G et al.
Journal of Chemotherapy (florence, Italy), 2004
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).
Aiello M et al.
Molecular Medicine Reports, 0
Select a paper to view details